India has put forth a draft policy plan to spur R&D and innovation in the biopharma and medtech segments, but effective implementation, political will to press ahead on some key proposals and seamless co-ordination between multiple agencies could be pivotal to ensure real gains.
India Proposes Faster Approvals, Bayh-Dole-Like Policy To Spur Innovation
Pricing Review Plans Also On The Menu
India’s draft policy to catalyze R&D and innovation seeks to create a “regulatory bias” towards innovation and aims to cut approval timelines sharply, among a raft of other proposals that include enabling differential pricing for “innovation with therapeutic benefits.” The Pink Sheet explores multiple nuances of the plan with industry experts.
